SIM0725 was independently developed by the company.
其自主研發的
Trajectories
Mine up to three arcs for this record — target, direction, probability, horizon.
This actor has not been a party to a decision yet.
Statements as reported by the cited publishers — not verified by DecisionGateway. Every row links to the source post.
SIM0725 was independently developed by the company.
其自主研發的
SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).
靶向白細胞介素-2受體β鏈(CD122)長效拮抗型單克隆抗體SIM0725
SIM0725 is intended for the treatment of autoimmune diseases.
擬用於治療自身免疫性疾病
SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.
已獲國家藥品監督管理局批准在中國開展臨牀試驗
Typed links extracted from the record corpus — not statements by this actor. Outgoing rows are links this actor acts on; “by” marks links directed at it.
Rows are ordered by the date on the record. Undated records are listed last, not dropped.